The UK MHRA reminds prescribers that rosiglitazone and pioglitazone should not be prescribed with insulin or in patients with heart failure.

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1028, 2004-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pioglitazone/rosiglitazone: Oedema and congestive heart failure: 6 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1022, 2004-01 ,pp. : 12-13

Adis International

Access to resources Recommend Favorite

Rosiglitazone may increase the risk of chronic heart failure (HF) in patients receiving insulin for type 2 diabetes mellitus

By  

Reactions Weekly, Vol. 1, Iss. 1030, 2004-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Pioglitazone/rosiglitazone: Liver failure: 17 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1292, 2010-01 ,pp. : 30-31

Adis International

Access to resources Recommend Favorite

Pioglitazone: Heart failure in elderly patients: 2 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1042, 2005-01 ,pp. : 16-17

Adis International

Access to resources Recommend Favorite

NZ Medsafe reminds prescribers of terbinafine-associated AEs

By  

Reactions Weekly, Vol. 1, Iss. 1128, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite